KDC-MN-141 – Kodiac biolabs

Plain-language summaryIntrigue 75 / 100

Bupropion, sold as Wellbutrin and Zyban, is an atypical antidepressant that inhibits dopamine and norepinephrine reuptake (an NDRI rather than an SSRI). Also FDA-approved for smoking cessation. Avoids the sexual side effects common to SSRIs. Not stocked by Kodiac. This monograph is provided for research and educational reference.

Intrigue 0–100 blends mechanism novelty, evidence strength, and translational potential. Kodiac editorial, not peer-reviewed.

Our opinion on this compoundEstablished workhorse

51/100

Mature FDA-approved NDRI with real bench utility but low novelty ceiling and aging mechanism

Bupropion sits in that uncomfortable middle zone for bench investigators. FDA-approved since 1985, mechanism fully characterized, metabolic pathway mapped to CYP2B6, clinical trial database enormous. By almost every dimension that bench scientists use to judge whether a compound deserves time, bupropion looks like a closed chapter. And mostly, it is.

The part that keeps it from dropping lower is the secondary pharmacology. The non-competitive nicotinic acetylcholine receptor antagonism, particularly at alpha-3-beta-4 and alpha-4-beta-2 subtypes, is a genuinely distinct action that single-mechanism NDRIs dont have. This is what drove its clinical utility in smoking cessation before varenicline arrived and demonstrated superior abstinence rates, and its also why pharmacology labs still reach for bupropion when they need to dissect nicotinic signaling from monoamine reuptake contributions in behavioral assays. Thats narrow bench value, but its real bench value.

The hydroxybupropion metabolite situation complicates clean in vitro work. The parent compound and its active metabolite have diverging receptor affinities and pharmacokinetic profiles, which means bupropion is messier as a probe than its reputation suggests. Investigators running acute monoamine studies often have to account for metabolite accumulation in a way that makes interpretation harder, not easier. We think this is underappreciated in the literature that treats bupropion as a simple NDRI tool.

Evidence quality is the strongest axis and also the most misleading one for library purposes. Multiple phase 3 RCTs, decades of post-market data, FDA approval across three indications including seasonal affective disorder. The Contrave combination (bupropion plus naltrexone) added a more recent layer of weight-loss data and raised some genuinely interesting questions about opioid-dopamine crosstalk in reward circuitry. But clinical approval history isnt the point of this library. A compound can have overwhelming clinical evidence and still be a poor research target, because all the interesting questions have already been answered.

Thats where bupropion lands. The mechanism is solved. The translational arrow is definitive. For a research program specifically interrogating CYP2B6-mediated oxidative metabolism, nicotinic receptor subtype pharmacology, or monoamine system dissection, bupropion is a legitimate tool to have. For anyone looking for a compound that opens new mechanistic questions in behavioral or metabolic neuroscience, honestly, theres not much here. The frontier moved on.

Novelty: 18
Mechanism promise: 42
In-category differentiation: 50
Evidence quality: 82
Translational signal: 75
Research bench value: 55

Rationale Bupropion scores well on evidence and translational signal because it’s a fully approved drug with four decades of RCT data, but novelty is structurally suppressed by its 1985 approval date and thoroughly characterized mechanism; the dual NDRI-plus-nicotinic-antagonist profile provides modest bench-tool value for monoamine and cholinergic dissection work, not enough to push into established-active territory.

Aminoketone NDRI / nicotinic antagonist

An aminoketone norepinephrine and dopamine reuptake inhibitor FDA-approved for depression (Wellbutrin) and smoking cessation (Zyban).

Abstract

Bupropion (Wellbutrin, Zyban; CAS 34911-55-2; molecular formula C13H18ClNO; molecular weight 239.74) is a unicyclic aminoketone developed by Burroughs Wellcome and approved by the FDA in 1985 for major depressive disorder, with subsequent approval for smoking cessation (1997) and seasonal affective disorder. Mechanism is selective inhibition of norepinephrine and dopamine reuptake (NDRI) plus non-competitive nicotinic acetylcholine receptor antagonism. The active metabolite hydroxybupropion contributes substantially to the antidepressant activity. Pharmacokinetics: parent half-life ~14 hours; CYP2B6 metabolism. Approved doses are 150 to 450 mg per day. Lowers seizure threshold; contraindicated in seizure disorders and bulimia.

Read the full monograph

The full reference document covers compound identification, discovery and developmental history, mechanism of action, pharmacokinetics, sourcing and quality verification, and a curated reference list. Embedded inline below; download for offline reading.

KDC-MN-141Open in new tab →

Download PDF →

FOR RESEARCH USE ONLY. Not for medical, diagnostic, or therapeutic purposes. Not for human consumption. All information is provided for research and educational purposes only.

Tag: KDC-MN-141

Bupropion

Abstract

Read the full monograph